Control of diseases with monoclonal antibodies'
The elegance of the method of monoclonal antibody production has been tempered in the field of oncology by the failure to find antibodies which are truly tumour-specific. This has not daunted investigators in the field who have used great ingenuity in developing a variety of interesting applications.
Perhaps the most advanced in terms of application to therapy of human cancer is the use of antibodies for treatment of bone marrow in vitro. Dr H G Prentice (Royal Free Hospital, London) described a method for preventing graftversus-host disease (GVHD), which occurs in more than 50% of recipients of allogeneic bone marrow transplants and is fatal in up to 25% of these despite the use of conventional immunosuppressive therapy. Dicke et al. (1968) and Rodt et al. (1981) showed that GVHD was abrogated if heteroantisera directed against T-cells were used to treat bone marrow in vitro before infusion into animals and man respectively. Dr Prentice reported the use of pan T-reactive murine monoclonal antibodies in three consecutive studies. In the first, the OKT3 murine monoclonal antibody reactive only with mature T-lymphocytes was used in patients having bone marrow transplants. Twenty-four percent of patients had severe GVHD (Prentice et al. 1982 ), suggesting some benefit from the treatment. In the second study rabbit complement was added to the OKT3 antibody with which the marrow was incubated. A mean of 71% T-cell killing was achieved and severe GVHD still occurred in 3 of 10 patients (Blacklock et al. 1983 ). In the third study a mixture of monoclonal antibodies eliminated >99% of T-lymphocytes from the donor marrow (Granger et al. 1982) . The effect of this regimen on GVHD is now being investigated (Prentice et al. 1984) . It is possible that this therapy may have application in the treatment of leukaemias expressing T-cell, B-cell and common acute lymphocytic leukaemia antigens. Tumour imaging after intravenous administration of radiolabelled antibody to tumour-associated antigens has perhaps received even more attention than treatment of bone marrow in vitro. Most work has been done with heteroantisera or mouse monoclonal antibodies. However, Dr H Smedley (Addenbrooke's Hospital, Cambridge) reported the use of rat monoclonal antibodies (Smedley et al. 1983) .
Rats were immunized with a purified membrane preparation derived from human colon carcinoma. Immunocytochemistry and immunochemical methods were used to test nine monoclonal antibodies. One, YPC2/12/1, bound to all colonic cancers tested as well as certain breast and lung carcinomata. These antibodies, in common with other well characterized antibodies directed against tumour-associated antigens, showed some binding to normal tissues, in this case bone marrow and colon. When radiolabelled and given intravenously, the antibody localized in xenografts of human colon carcinoma growing in immunosuppressed mice. Imaging studies have been performed in 30 patients with advanced colorectal cancer. For these the antibody was labelled with 131-iodine and background antibody distribution subtracted using the method of Goldenberg et al. (1978) . The smallest tumours localized were 1 cm diameter. This compares well with the best results reported with different antibodies (for review see Begent & Bagshawe 1983) .
Human monoclonal antibodies were also the topic of the presentation by Dr J V Watson (Addenbrooke's Hospital, Cambridge). Lymphocytes were separated from human glioma tumour tissue and fused with human myeloma cell line to produce human monoclonal antibody (11D6). Radiolabelled 1D6 was shown to localize in a primary cerebral glioma after intravenous administration. Dr Watson described the use of a chamber which contains the human antibody hybridoma cell line. This was implanted subcutaneously into the abdominal wall of patients (Sikora et al. 1982) and was shown to continue antibody production for at least three months. This antibody can also be detected in the patient's serum for a similar duration. The possibilities of treating human cancer in this way were discussed, together with the ethical questions posed by implantation of a myeloma cell line into patients. Scrapie is a slowly progressive, fatal, noninflammatory degeneration of the central nervous system, characterized histopathologically by bilaterally symmetrical spongiform encephalopathy, with destruction of nerve cells, gliosis, and hypertrophy of astrocytes. It is experimentally transmissible to sheep, goats, mice, rats and hamsters, with an incubation period ranging from months to years. Cuille & Chelle (1936) found that the transmissible agent would pass a Chamberland L3 filter. A virus was postulated, but -48 years laterno virus has been found. Indeed, the agent is now known to have important non-viral properties; in particular it appears to lack nucleic acid. After many years' experimental work with scrapie, Jones and I suggested in 1967 that 'the transmissible agent may be, or may be associated with, a small basic protein'. This conclusion was considered nonsense, and the search for a virus was continued by all except ourselves. However, the intriguing problems of scrapie brought new workers into the field, and in 1982 American biochemist Prusiner published extensive studies with a wide review of the literature under the title 'Novel proteinaceous particles cause scrapie'. He drew attention to problems of purification of the agent, emphasized its hydrophobicity, heat stability, and low molecular weight, and gave convincing evidence of its protein nature. He coined the word 'prion' to distinguish it from viruses, viroids, and plasmids. He speculated on how the agent could reproduce disease when passed from animal to animal ('replicate'), and commented: 'The molecular mechanism by which prions might activate cellular genes which code for their biosynthesis is unknown. The emerging story of oncogenes within retroviruses and their cellular counterparts provides an interesting analogy'.
Letters to the Editor
It is understandable that biochemist Prusiner would be less concerned with the pathogenesis of scrapie than with the nature of its transmissible agent. He did not mention that brain tissue cells from scrapie-affected animals grow in vitro much more readily than similar cells from normal animals (Field & Windsor 1965 , Pattison & Haig 1967 . Haig and I were impressed by the neoplastic appearance of organ cultures of scrapie mouse brain. Again, Prusiner did not note that the earliest detectablehistological abnormality in experimental scrapie is bilaterally symmetrical hypertrophy of astrocytes, initiating the characteristic pathology of the disease (Pattison 1965) . These observations suggest that scrapie has more in common with neoplastic than with inflammatory disease.
The review that stimulated this letter draws attention to the possible involvement of growth factors in transformation of cells. There are significant similarities between platelet-derived growth factor and the scrapie agent. I suggested in 1982 that the agent might be a gene, and emphasized the well established fact that naturally-occurring scrapie in sheep is under genetic control. I now think that this new work with oncogenes provides the clue that has so long eluded those who have been mystified by scrapie. 
